Get the Stockscreener App
98.47
2.99%
-3.03
After Hours:
98.50
0.03
+0.03%
Overview
News
Price History
Option Chain
Financials
Why RVTY Down?
Discussions
Forecast
Stock Split
Dividend History
Revvity Inc stock is traded at $98.47, with a volume of 1.14M.
It is down -2.99% in the last 24 hours and up +5.28% over the past month.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
See More
Previous Close:
$101.50
Open:
$100.37
24h Volume:
1.14M
Relative Volume:
0.90
Market Cap:
$11.61B
Revenue:
$2.77B
Net Income/Loss:
$286.61M
P/E Ratio:
41.90
EPS:
2.35
Net Cash Flow:
$524.11M
1W Performance:
-0.24%
1M Performance:
+5.28%
6M Performance:
-18.44%
1Y Performance:
-10.09%
1-Day Range:
$98.31
$101.36
1-Week Range:
$97.84
$104.12
52-Week Range:
$87.70
$129.50
Revvity Inc Stock (RVTY) Company Profile
Name
Revvity Inc
Sector
Industry
Phone
781-663-6900
Address
77 4TH AVENUE, WALTHAM
Compare RVTY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RVTY
Revvity Inc
|
98.47 | 11.63B | 2.77B | 286.61M | 524.11M | 2.35 |
|
TMO
Thermo Fisher Scientific Inc
|
425.34 | 158.06B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
197.75 | 142.87B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
531.42 | 43.87B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
120.08 | 33.87B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
160.13 | 28.10B | 15.50B | 1.33B | 2.16B | 7.34 |
Revvity Inc Stock (RVTY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-01-25 | Upgrade | UBS | Neutral → Buy |
| Jan-10-25 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Dec-13-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-15-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-28-24 | Initiated | Wells Fargo | Equal Weight |
| Jul-08-24 | Initiated | Leerink Partners | Outperform |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | UBS | Buy → Neutral |
| Jan-04-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-19-23 | Initiated | Raymond James | Outperform |
| May-23-23 | Resumed | Goldman | Buy |
View All
Revvity Inc Stock (RVTY) Latest News
Reflecting On Research Tools & Consumables Stocks’ Q1 Earnings: Revvity (NYSE:RVTY) - Yahoo Finance
Revvity (RVTY) Shares Soar 1.98% on Clinical Trial Success - AInvest
Evercore ISI Adjusts Price Target on Revvity to $115 From $116, Maintains Outperform Rating - MarketScreener
(RVTY) Trading Advice - news.stocktradersdaily.com
Revvity to Hold Earnings Call on Monday, July 28, 2025 - Business Wire
Should You Investigate Revvity, Inc. (NYSE:RVTY) At US$101? - simplywall.st
5 Insightful Analyst Questions From Revvity’s Q1 Earnings Call - Yahoo Finance
What 9 Analyst Ratings Have To Say About Revvity - Benzinga
Barclays Keeps Their Buy Rating on Revvity (RVTY) - The Globe and Mail
Is Revvity Stock Underperforming the Dow? - MSN
Is Revvity Stock Underperforming the Dow? A Case for Undervaluation and Growth - AInvest
An Intrinsic Calculation For Revvity, Inc. (NYSE:RVTY) Suggests It's 39% Undervalued - Yahoo Finance
Revvity Inc. stock outperforms competitors despite losses on the day - MarketWatch
How To Trade (RVTY) - news.stocktradersdaily.com
Are Revvity, Inc.'s (NYSE:RVTY) Mixed Financials Driving The Negative Sentiment? - simplywall.st
Revvity introduces new IVD reference standards for monitoring oncology diagnostic testing workflows - SelectScience
Revvity Inc. stock outperforms competitors on strong trading day - MarketWatch
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus By Investing.com - Investing.com Canada
Revvity at Goldman Sachs Conference: Diagnostics and Software Focus - Investing.com
Transcript : Revvity, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener
Revvity To Present At Goldman Sachs Global Healthcare Conference; Webcast At 8:00 AM ET - Nasdaq
Wellington Management Group LLP Has $743,000 Stock Holdings in Revvity, Inc. (NYSE:RVTY) - Defense World
(RVTY) Long Term Investment Analysis - news.stocktradersdaily.com
Revvity gets FDA nod for its automated tuberculosis test - MSN
4 Mass. Rulings You May Have Missed In May - Law360
Revvity (RVTY) Introduces New Mimix Standards for Improved IVD Testing | RVTY Stock News - GuruFocus
New Cancer Testing Standards from Revvity Promise More Accurate Diagnostic Results for Oncology Labs - Stock Titan
Revvity Introduces New IVD Reference Standards for Monitoring Oncology Diagnostic Testing Workflows - Yahoo Finance
Insider Sell: Michelle Mcmurry-heath Sells 600 Shares of Revvity Inc (RVTY) - GuruFocus
Does The Market Have A Low Tolerance For Revvity, Inc.'s (NYSE:RVTY) Mixed Fundamentals? - Yahoo
Millennium Management LLC Trims Position in Revvity, Inc. (NYSE:RVTY) - Defense World
Rise of the Undervalued: Why Revvity (RVTY) Is Poised for a Turnaround Play - AInvest
Shareholders in Revvity (NYSE:RVTY) are in the red if they invested three years ago - simplywall.st
Revvity Inc (RVTY) Shares Up 3.52% on May 27 - GuruFocus
Revvity, Inc. (NYSE:RVTY) Shares Purchased by Cetera Investment Advisers - Defense World
RVTY Stock Falls Despite the Latest Launch of Automated Instrument - MSN
Revvity (NYSE:RVTY) Cut to “Hold” at Wall Street Zen - Defense World
Zacks Research Forecasts Revvity’s Q1 Earnings (NYSE:RVTY) - Defense World
Revvity’s EUROIMMUN unveils new fully automated instrument for specialty testing - SelectScience
Revvity’s EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing - Technology Networks
Enhancing Laboratory Efficiency with Revvity's IDS i20™ Platform - Lab Manager
Is Wall Street Bullish or Bearish on Revvity Stock? - inkl
Is Wall Street Bullish Or Bearish On Revvity Stock? - Barchart.com
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlo - GuruFocus
Revvity (RVTY) Receives Affirmed Buy Rating with Promising Outlook | RVTY Stock News - GuruFocus
Sustainable chemistry in India fueling growth with digital and AI innovation: Revvity Signals - Indian Chemical News
Ameriprise Financial Inc. Increases Stock Position in Revvity, Inc. (NYSE:RVTY) - Defense World
Revvity announces launch of new fully automated instrument for specialty testing - BioSpectrum India
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for S - GuruFocus
Revvity's EUROIMMUN Unveils New Fully Automated Instrument for Specialty Testing | RVTY Stock News - GuruFocus
Revvity's New Automated Platform Transforms Specialty Disease Testing with 20-Analyte Capability - Stock Titan
Revvity Inc Stock (RVTY) Financials Data
Revenue
Net Income
Cash Flow
EPS
13.81%
0.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):